Answers are grounded in this paper and cite their sources.
The matrix metalloproteinases (MMPs) are a family of zinc containing endopeptidases that degrade various components of the extra cellular matrix. Among the many types of MMPs that have been identified, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are thought to play a key role in cancer metastasis. These MMPs are able to modify tumor microenvironment by degrading type IV collagen found in the cellular basement membrane. MMP-2 and -9 are essential in facilitating cancer cell invasion, tumor progression, and metastasis, thereby shortening patient survival in all cancer types. A significant association has been reported between tumor aggression and increased levels of MMP-2 and MMP-9. Therefore, MMPs are used as diagnostic and prognostic biomarkers in many clinical trials and experimental studies. MMP inhibitors (MMPIs) seem to be the logical targets for the therapeutic intervention in cancer. The rationale for developing MMPIs for halting cancer has been around for more than three decades. However, the clinical trials of synthetic MMPIs have not produced favorable results.
No takes yet. Share an insight, caveat, or question.
A 2015 study studied this question.
Synapse has enriched 6 related papers. Consider them for comparative context: